GLUE:NASDAQMonte Rosa Therapeutics, Inc. Analysis
Data as of 2026-09-27 - not real-time
$11.77
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Monte Rosa Therapeutics, Inc. is priced at $11.77 and its moving averages line up in bearish order, the shorter trailing the longer. Across the trailing 30 sessions it lost 25.7%. Relative strength is 29.0 — oversold — and the MACD signal is bearish. Recent trading has carved out support near $11.41 and resistance around $15.00.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 142.1% above today's level. Revenue is contracting at 61.3%.
Risk scores 8 out of 10, which is high for this asset class. With 30-day volatility of 52.4%, a beta of 0.79 and a maximum drawdown of 53.7%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 2/10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 142.1% above today's level. Revenue is contracting at 61.3%.
Risk scores 8 out of 10, which is high for this asset class. With 30-day volatility of 52.4%, a beta of 0.79 and a maximum drawdown of 53.7%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 2/10.
Top Market Events
Monte Rosa Therapeutics, Inc. recently reported second-quarter 2026 results showing a net loss of US$43.4 million, up...GLUE stock of Monte Rosa Therapeutics, Inc.On September 8, Monte Rosa Therapeutics NASDAQ:GLUE announced that Novartis NYSE:NVS , its partner on a VAV1-targeted...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 3/10
Key Factors
- Short-term moving averages stacked below long-term ones
- RSI at 29.0 signals oversold conditions
- Trading below the 200-day average of 18.33
Medium Term
1–3 yearsNeutral
Model confidence: 2/10
Key Factors
- Short-term moving averages stacked below long-term ones
- RSI at 29.0 signals oversold conditions
- Trading below the 200-day average of 18.33
Long Term
> 3 yearsNeutral
Model confidence: 2/10
Key Factors
- Analyst targets imply +142.1% versus the current price
- Negative return on equity of -42.7%
- Revenue contracting at -61.3%
Key Metrics & Analysis
Financial Health
Revenue Growth-61.30%
P/E Ratio-6.3
ROE-42.66%
ROA-21.63%
Debt/Equity7.80
P/B Ratio2.1
Op. Cash Flow$-24069000
Free Cash Flow$-74449752
Industry P/E30.5
Technical Analysis
TrendBearish
RSI29.0
Support$11.41
Resistance$15.00
MA 20$13.28
MA 50$16.04
MA 200$18.33
MACDBearish
VolumeIncreasing
Fear & Greed Index94.88
Valuation
Target Price$28.50
Upside/Downside142.14%
GradeFair
TypeBlend
Risk Assessment
Beta0.79
Volatility52.39%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.